CAMP (Camp4 Therapeutics) Change In Receivables: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAMP Camp4 Therapeutics Corp CAMP
8 GF Score
Price $4.49
! 4 Warning Signs
View Full Analysis

What is Camp4 Therapeutics Change In Receivables?

Camp4 Therapeutics CAMP +0.67% 8 Change In Receivables is $0.00 Mil as of Jun. 2026. GuruFocus rates CAMP with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

Camp4 Therapeutics's change in receivables for the quarter that ended in Jun. 2026 was $0.00 Mil. It means Camp4 Therapeutics's Accounts Receivable stayed the same from Mar. 2026 to Jun. 2026 .

Camp4 Therapeutics's change in receivables for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means Camp4 Therapeutics's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

Camp4 Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2026 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Camp4 Therapeutics's Days Sales Outstanding for the three months ended in Jun. 2026 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Camp4 Therapeutics's liquidation value for the three months ended in Jun. 2026 was $-7.72 Mil.

Camp4 Therapeutics  (NAS:CAMP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Camp4 Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/1.779*91
=0.00

2. In Ben Graham's calculation of liquidation value, Camp4 Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Camp4 Therapeutics's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=86.398-94.121+0.75 * 0+0.5 * 0
=-7.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camp4 Therapeutics Change In Receivables Related Terms

Camp4 Therapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Camp4 Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camp4 Therapeutics Change In Receivables Chart

Camp4 Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Change In Receivables
0.00 0.00 0.00 0.00

Camp4 Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CAMP
8GF Score
Camp4 Therapeutics Corp CAMP
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Camp4 Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.00 Mil mean?
Camp4 Therapeutics (CAMP) has a Change In Receivables of $0.00 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Camp4 Therapeutics and its competitors.
Is Camp4 Therapeutics' Change In Receivables too high?
Camp4 Therapeutics' current Change In Receivables is $0.00 Mil. Overall, Camp4 Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Camp4 Therapeutics' Change In Receivables compare to ALEC and ORMP?
Camp4 Therapeutics' Change In Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Camp4 Therapeutics and its competitors. Camp4 Therapeutics's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camp4 Therapeutics stock overvalued right now?
Camp4 Therapeutics (CAMP) has a current Change In Receivables of $0.00 Mil. The current Change In Receivables is $0.00 Mil. Camp4 Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Camp4 Therapeutics (CAMP), the current Change In Receivables is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Camp4 Therapeutics Business Description

Address One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA, 02139
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
8GF Score

Get the complete analysis for CAMP

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.49
Price